Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.

Infection - 1 Apr 2014

Caby F, Schneider L, Blanc C, Soulié C, Tindel M, Peytavin G, Agher R, Valantin M A, Tubiana R, Wirden M, Calvez V, Marcelin A G, Katlama C

Abstract excerpt

BACKGROUND AND PURPOSE: The lack of antiretroviral (ARV) backbone activity associated with raltegravir has been proposed as the main explanation for virological relapse observed in patients with undetectable viraemia who are switched from a ritonavir-boosted protease inhibitor (PI) to raltegravir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to France
Share to HIV

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Ritonavir

Share to Viremia

Source

Identifiers

PMID: 24155032
DOI: 10.1007/s15010-013-0542-8

Genes

GSS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24155032-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.PMID 24155032Read ↗

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.Semantic proximity Read ↗

Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.Semantic proximity Read ↗

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.Semantic proximity Read ↗

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.Semantic proximity Read ↗

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.Semantic proximity Read ↗

Virologic Outcomes of Switching to Dolutegravir Functional Monotherapy, or Functional Dual Therapy With Dolutegravir Plus A Non-cytosine Nucleoside Analog: A Retrospective Study of Treatment-Experienced, HIV-1 Infected PatientsSemantic proximity Read ↗

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.Semantic proximity Read ↗

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.Semantic proximity Read ↗

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.Semantic proximity Read ↗

Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance TestingSemantic proximity Read ↗

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.Semantic proximity Read ↗

Safety and Effectiveness of Switching to Abacavir/Lamivudine Plus Rilpivirine for Maintenance Therapy in Virologically Suppressed HIV-1 Patients in Singapore (SEALS)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.